Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomised double blind placebo controlled clinical trial of anti-B-cell therapy in patients with primary Sjogrens syndrome

Next Previous
Trial Profile

A randomised double blind placebo controlled clinical trial of anti-B-cell therapy in patients with primary Sjogrens syndrome

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 14 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rituximab (Primary)
  • Indications Sjogren's syndrome
  • Focus Therapeutic Use
  • Acronyms TRACTISS

Most Recent Events

  • 10 Dec 2023 Results assessing to identify peripheral and salivary gland (SG) biomarkers of response/resistance to B-cell depletion based on the novel concise CRESS and candidate STAR composite endpoints in TRACTISS trial of Sjogren's syndrome, published in the Arthritis and Rheumatology.
  • 04 Jun 2022 Results (n=29)of first longitudinal analysis of matched transcriptomic and histological data of SG biopsies of pSS patients treated with RTX vs placebo at 3 time points, over 48 weeks, presented at the 23rd Annual Congress of the European League Against Rheumatism
  • 09 Nov 2021 Results from two RCTs ASAP-III and TRACTISS trials in Patients with Primary Sjogren's Syndrome presented at the ACR Convergence 2021

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top